在炎症性肠病患者的粘膜基因表达:新的见解
Sumaiah J Alarfaj1, Sally Abdallah Mostafa2, Walaa A Negm3
1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
炎症性肠道疾病 (IBD) 的治疗方法,如5-ASA和抗TNF药物,可以减少肠道粘膜中的关键炎症生物标志物. 这两种疗法都能使过度表达的蛋白质正常化,而抗TNF药物也能恢复ABCB1和E-cadherin的正常水平.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 的特点是疾病严重程度,进展和治疗反应的显著个体变化.
- 肠上皮屏障的破坏是IBD的主要原因,使粘膜基因表达成为研究的关键领域.
- 肠道活检的分子分析提供了一种敏感和可靠的方法来评估局部炎症和识别生物标志物.
研究的目的:
- 在接受5氨基酸 (5-ASA) 或抗TNF疗法治疗的IBD患者中调查粘膜基因表达的改变.
- 为了比较5-ASA和抗TNF药物对炎症肠道组织中特定IBD相关基因的表达的影响.
- 识别响应IBD不同治疗干预的分子标记物.
主要方法:
- 量化聚合酶链反应 (qPCR) 用于评估多个IBD相关基因的粘膜表达.
- 在接受5-ASA (N=39) 或抗TNF (N=22) 治疗的IBD患者的肠道活检中分析了基因表达水平.
- 治疗IBD患者和非IBD患者之间的表达水平进行了比较,以及不同治疗组之间的表达水平.
主要成果:
- 5-ASA和抗TNF疗法都显著降低了IBD粘膜炎症中的Lipocalin-2 (LCN2),氧化合成酶2 (NOS2),mucin 2 (MUC2),mucin 5AC (MUC5AC) 和树叶因子1 (TFF1) 的过度表达.
- 发现抗TNF疗法可以使IBD患者的ABCB1和E-cadherin水平恢复到正常水平.
- 这些发现表明,不同IBD治疗方式的分子反应不同.
结论:
- 5-ASA和抗TNF疗法调节IBD患者肠道粘膜中的关键炎症基因表达.
- 这两种治疗方案都有效地降低了与活性IBD相关的特定上调蛋白质.
- 抗TNF药物表现出更广泛的效果,使ABCB1和E-cadherin等额外的基因正常化,这表明了不同的作用机制.
更多相关视频
06:31Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
10:37Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
